For a higher level of PCR excellence
Fast, actionable data with most test results in less than an hour and respiratory test results in as little as 30 minutes* |
Highly accurate PCR results for consistent patient management across the continuum of care |
On-demand and random-access allows tests to be performed when needed rather than being delayed for batch testing |
Cepheid provides a higher level of PCR excellence that is designed to deliver speed, accuracy, and peace of mind.
Tests from Cepheid that can help you meet today’s infection control challenges
Antimicrobial resistance (AMR) including multidrug-resistant organism (MDRO)
Carbapenem Resistance (KPC, NDM, VIM, OXA-48 and IMP)
Vancomycin-Resistant Enterococci (VRE)
|
Healthcare Associated Infections (HAIs)
Central Line- Associated Bloodstream Infection (CLABSI)
Clostridioides difficile Infection (CDI)
Surgical Site Infection (SSI)
|
Disease/Organism Chlamydia trachomatis and Neisseria gonorrhoeae
Clostridioides difficile (C. diff)
Enterococcus (Vancomycin-Resistant)
Influenza and/or COVID-19
Methicillin Susceptible Staphylococcus aureus (MSSA) and/or Methicillin Resistant Staphylococcus aureus (MRSA)
Mycobacterium tuberculosis (MTB)
Norovirus
|

References
All tests listed are non-waived unless otherwise stated.
* Test times may vary, refer to product package insert for testing time details.
^ In Vitro Diagnostic devices for use in High and Moderate Complexity or CLIA waived patient care settings. See Package Inserts for details.
# These tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2 plus has been authorized only for the detection of nucleic acids from SARS-CoV-2, and not for any other viruses or pathogens. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
† For positives when running SARS-CoV-2 only, using Xpert Xpress CoV-2/Flu/RSV plus; otherwise, the test will have a runtime of approximately 36 minutes.
‡ With early assay termination (EAT) for positive results; otherwise, the full test runtime is approximately 30 minutes.
§ With early assay termination (EAT) for positive results.
US-IVD. In Vitro Diagnostic Medical Device